Verastem (VSTM) Current Assets (2011 - 2026)
Verastem (VSTM) posted quarterly Current Assets of $202.9 million for Q1 2026, up 62.72% year-over-year from $124.7 million in Q1 2025, and down 9.18% quarter-over-quarter from $223.4 million in Q4 2025.
Analysis
Verastem (VSTM) Current Assets (2011 - 2026) Analysis & Trends
Verastem's Current Assets history runs 16 years deep, the most recent figure standing at $202.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 62.72% year-over-year to $202.9 million; the TTM figure through Mar 2026 stood at $202.9 million (up 62.72% YoY), while the FY2025 annual figure was $223.4 million, up 135.27% from the prior year.
- Current Assets for Q1 2026 stood at $202.9 million, down from $223.4 million in the prior quarter.
- The five-year high for Current Assets was $223.4 million in Q4 2025, with the low at $92.9 million in Q4 2022.
- The 5-year median for Current Assets is $120.7 million (2024), against an average of $138.4 million.
- The sharpest annual moves came in 2024 and 2025: Current Assets tumbled 47.54% in 2024, then soared 135.27% in 2025.
- Verastem's Current Assets stood at $92.9 million in 2022, then surged by 54.71% to $143.7 million in 2023, then plunged by 33.91% to $95.0 million in 2024, then jumped by 135.27% to $223.4 million in 2025, then slipped by 9.18% to $202.9 million in 2026.
- Business Quant data shows VSTM's Current Assets at $202.9 million in Q1 2026, $223.4 million in Q4 2025, and $154.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 176.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 176.16 Mn |
| Mar 31, 2026 | 202.90 Mn |
| Dec 31, 2025 | 223.41 Mn |
| Sep 30, 2025 | 154.06 Mn |
| Jun 30, 2025 | 174.27 Mn |
| Mar 31, 2025 | 124.70 Mn |
| Dec 31, 2024 | 94.96 Mn |
| Sep 30, 2024 | 120.66 Mn |
| Jun 30, 2024 | 99.65 Mn |
| Mar 31, 2024 | 117.67 Mn |
| Dec 31, 2023 | 143.68 Mn |
| Sep 30, 2023 | 174.49 Mn |
| Jun 30, 2023 | 189.96 Mn |
| Mar 31, 2023 | 118.89 Mn |
| Dec 31, 2022 | 92.87 Mn |
| Sep 30, 2022 | 108.76 Mn |
| Jun 30, 2022 | 97.88 Mn |
| Mar 31, 2022 | 113.44 Mn |
| Dec 31, 2021 | 105.74 Mn |
| Sep 30, 2021 | 108.76 Mn |